GlassScriptPhysician profile
Stephen Thomas Iuliano
NPI 1720090384
$1,214.41
in general payments reported to CMS, 2019-2025
20 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.97 · 2022: $47.19 · 2023: $309 · 2024: $326 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $240.49 | 2023-2025 | |
| Pfizer INC. | $129.93 | 2025 | |
| Medtronic, INC. | $110.13 | 2025 | Aurora Ev-Icd Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.54 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $89.99 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor, Rezum Generator |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.60 | 2022-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $75.21 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $61.67 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $50.65 | 2023-2025 | Camzyos, Eliquis |
| Ge Healthcare | $46.97 | 2019 | |
| Amgen INC. | $30.50 | 2023 | Repatha |
| Sumitomo Pharma America, INC. | $28.71 | 2024 | Gemtesa |
| Novo Nordisk INC | $27.74 | 2025 | Wegovy |
| Watermark Medical, INC. | $22.70 | 2024 | |
| Lantheus Medical Imaging, INC. | $22.36 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.15 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.74 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $20.51 | 2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $19.17 | 2023 | Optimizer |
| Glaxosmithkline, LLC. | $14.65 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Iuliano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.